Compare Gold Fields Limited (GFI) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gold Fields Limited vs BIO-TECHNE Corp — how do they compare? Gold Fields Limited trades at $32.01 (market cap $29.07B), while BIO-TECHNE Corp trades at $71.56 (market cap $11.14B). The key difference: Gold Fields Limited is far larger — about 2.6× BIO-TECHNE Corp's market cap, and Gold Fields Limited pays the higher dividend (7.03%). Which is the better fit depends on your goals.
| GFI | TECH | |
|---|---|---|
Market Cap | $29.07B | $11.14B |
Sector | Basic Materials | Health |
52-Week High | $61.52 | $71.48 |
52-Week Low | $23.95 | $43.31 |
Enterprise Value | $30.51B | $11.22B |
Dividend Yield | 7.03% | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gold Fields (GFI) trades at $33.33, down 0.6% with a bearish technical signal despite strong fundamental metrics including a P/E of 8.37, net income margin of 40.76%, and ROE of 52.33%. Recent earnings show mixed results with a Q1 2025 beat but subsequent misses. The company demonstrates robust cash flow growth with 2025 operating cash flow projected at $3.8B, while technical indicators show oversold conditions with RSI at 26.87.
GFI presents a compelling value opportunity with attractive valuation multiples and exceptional profitability metrics, though recent earnings misses and bearish technical momentum create near-term uncertainty. The 57% upside to the $52.75 consensus price target suggests significant potential, but investors should monitor operational execution and gold price volatility as key risk factors.
Bio-Techne Corporation (TECH) trades at $71.66, near its all-time high, following Merck KGaA's announced $73 per share cash acquisition offer, representing a 24% premium. The stock shows a bullish technical trend, while fundamental metrics reveal a high valuation with a P/E of 102.12 and a net income margin of 9.05%. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. Analyst consensus is evenly split between Buy and Hold, with a $67.75 price target below the current offer price.
The investment outlook is dominated by the pending acquisition by Merck KGaA. The primary opportunity is the realization of the $73 per share offer, providing a clear exit near current levels. Key risks include potential deal completion delays, regulatory scrutiny, and shareholder litigation questioning the fairness of the price. Should the deal fall through, the stock faces significant downside pressure given its stretched valuation and recent earnings volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
